Kiseleva I V, Larionova N V, Teley L C P, Rudenko L G
Vopr Virusol. 2011 May-Jun;56(3):28-32.
Live attenuated cold-adapted influenza vaccine (LIV) has been used in Russia for over 50 years and proved to be safe and effective. Currently, Russian reassortant LAIV is based on influenza AILeningrad/134/17/57 (H2N2) and B/USSR/60/69 Master Donor Viruses (MDVs) which are cold-adapted (ca), temperature-sensitive (ts), and attenuated (att), respectively. The MDVs are used to generate attenuated reassortant vaccine viruses containing the surface antigens of current wild type (wt) influenza A (HINI) and A (H3N2) viruses and wt influenza B virus. The ca/ts/att phenotype of these viruses limits replication in the upper respiratory tract. Reassortment typically yields numerous viruses with different genome constellations, rapid screening is needed to select proper vaccine viruses. In this study, screening of reassortant vaccine strains for live attenuated influenza vaccine generated from currently circulating influenza A and B viruses by RFLP assay is described.
减毒活冷适应流感疫苗（LIV）在俄罗斯已使用超过50年，且被证明是安全有效的。目前，俄罗斯重组减毒活流感疫苗基于甲型流感列宁格勒/134/17/57（H2N2）和乙型流感/苏联/60/69主供体病毒（MDVs），它们分别是冷适应（ca）、温度敏感（ts）和减毒（att）的。这些MDVs用于产生含有当前野生型（wt）甲型流感（HINI）和甲型流感（H3N2）病毒以及野生型乙型流感病毒表面抗原的减毒重组疫苗病毒。这些病毒的ca/ts/att表型限制了其在上呼吸道中的复制。重组通常会产生许多具有不同基因组组合的病毒，因此需要快速筛选以选择合适的疫苗病毒。在本研究中，描述了通过限制性片段长度多态性（RFLP）分析筛选由当前流行的甲型和乙型流感病毒产生的减毒活流感疫苗的重组疫苗株。
